Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection

Peer Review reports

Original Submission
4 Sep 2020	Submitted	Original manuscript
12 Oct 2020	Reviewed	Reviewer Report - Omar Sued
1 Jun 2021	Reviewed	Reviewer Report - Alvaro Lopez
22 Jun 2021	Author responded	Author comments - Vasiliki Chounta
Resubmission - Version 2
22 Jun 2021	Submitted	Manuscript version 2
15 Sep 2021	Reviewed	Reviewer Report
7 Jan 2022	Author responded	Author comments - Vasiliki Chounta
Resubmission - Version 3
7 Jan 2022	Submitted	Manuscript version 3
2 Mar 2022	Author responded	Author comments - Vasiliki Chounta
Resubmission - Version 4
2 Mar 2022	Submitted	Manuscript version 4
Publishing
4 Mar 2022	Editorially accepted
4 May 2022	Article published	10.1186/s12879-022-07243-3

Back to article page